Stock Worth Watching: Does Momenta Pharmaceuticals, Inc. Have Any Gas After Today’s Big Increase?

Stock Worth Watching: Does Momenta Pharmaceuticals, Inc. Have Any Gas After Today's Big Increase?

The stock of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) is a huge mover today! About 383,052 shares traded hands. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has risen 42.32% since March 8, 2016 and is uptrending. It has outperformed by 33.01% the S&P500.
The move comes after 9 months positive chart setup for the $924.79 million company. It was reported on Oct, 11 by We have $16.18 PT which if reached, will make NASDAQ:MNTA worth $240.45 million more.

Analysts await Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) to report earnings on November, 2. They expect $-0.28 EPS, up 36.36% or $0.16 from last year’s $-0.44 per share. After $-0.31 actual EPS reported by Momenta Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -9.68% EPS growth.

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Ratings Coverage

Out of 8 analysts covering Momenta Pharmaceuticals (NASDAQ:MNTA), 4 rate it a “Buy”, 2 “Sell”, while 2 “Hold”. This means 50% are positive. $31 is the highest target while $6 is the lowest. The $17.44 average target is 35.83% above today’s ($12.84) stock price. Momenta Pharmaceuticals has been the topic of 15 analyst reports since August 6, 2015 according to StockzIntelligence Inc. Maxim Group downgraded the shares of MNTA in a report on Wednesday, September 7 to “Sell” rating. The company was maintained on Wednesday, May 4 by Leerink Swann. On Monday, June 6 the stock rating was initiated by Goldman Sachs with “Neutral”. The firm has “Outperform” rating given on Tuesday, October 13 by Leerink Swann. The rating was upgraded by Maxim Group to “Hold” on Friday, January 8. The stock of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has “Neutral” rating given on Thursday, August 6 by Goldman Sachs. Barclays Capital initiated the shares of MNTA in a report on Monday, November 23 with “Equal-Weight” rating. The firm has “Overweight” rating by JP Morgan given on Friday, November 13.

According to Zacks Investment Research, “Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. Momenta is also utilizing its ability to sequence sugars to create technology-enabled generic products.”

Insitutional Activity: The institutional sentiment increased to 1.38 in Q2 2016. Its up 0.21, from 1.17 in 2016Q1. The ratio improved, as 23 funds sold all Momenta Pharmaceuticals, Inc. shares owned while 30 reduced positions. 15 funds bought stakes while 58 increased positions. They now own 57.30 million shares or 1.40% less from 58.11 million shares in 2016Q1.
Stifel Financial Corporation holds 0% or 26,451 shares in its portfolio. Pub Employees Retirement Association Of Colorado, a Colorado-based fund reported 15,811 shares. Pacad Inv has invested 0.01% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Pnc Finance Services Gru reported 169,060 shares or 0% of all its holdings. Credit Suisse Ag last reported 74,191 shares in the company. Eqis Management last reported 0.02% of its portfolio in the stock. Amica Pension Fund Board Of Trustees last reported 72,382 shares in the company. Sabby Mgmt Limited Liability Company accumulated 0.08% or 145,600 shares. Numeric Investors Limited Liability Com accumulated 0.05% or 536,730 shares. Moreover, Loring Wolcott & Coolidge Fiduciary Ltd Liability Partnership Ma has 0% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 2,000 shares. Ls Ltd holds 0% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 2,648 shares. The Washington-based Parametric Portfolio Associate Ltd Liability Corp has invested 0% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Laurion Management Ltd Partnership has 18,000 shares for 0% of their US portfolio. Sectoral Asset Mngmt Incorporated last reported 574,040 shares in the company. Blackrock Institutional Tru Na holds 0% or 1.61M shares in its portfolio.

Insider Transactions: Since April 18, 2016, the stock had 0 insider purchases, and 12 selling transactions for $314,999 net activity. 784 Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shares with value of $7,997 were sold by Bishop John E. WHEELER CRAIG A sold $70,704 worth of stock. The insider Leicher Bruce sold $12,415. On Wednesday, June 1 Shapiro Bennett M sold $67,600 worth of the stock or 5,200 shares. The insider Kaundinya Ganesh Venkataraman sold $10,690. $13,151 worth of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) was sold by Roach James M. on Friday, August 19. Shares for $9,904 were sold by Shea Richard P.

More notable recent Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) news were published by: which released: “Momenta Pharmaceuticals, Inc.: Good News from Courts and the FDA Ahead?” on August 09, 2016, also with their article: “Why Momenta Pharmaceuticals, Inc. Was Up Today” published on January 08, 2016, published: “Momenta Pharmaceuticals Inc. Shed a Third of Its Value in February — Here’s Why” on March 04, 2016. More interesting news about Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) were released by: and their article: “Why Momenta Pharmaceuticals, Inc. Earned a Lower Price Today” published on February 18, 2016 as well as‘s news article titled: “Momenta Pharmaceuticals Appoints Corey N. Fishman to Board of Directors” with publication date: September 23, 2016.

MNTA Company Profile

Momenta Pharmaceuticals, Inc., incorporated on May 17, 2001, is a biotechnology company. The Firm is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Firm focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. The Firm has developed generic version of Lovenox (enoxaparin sodium injection).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment